SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.

Gut · 2014 · PMC4033275 · PMID 24067278

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

failed to reach significancep=0.09so close (0.05 < p ≤ 0.1)

nab -Paclitaxel and cremophor-paclitaxel decreased overall proliferation rate of KPC tumours marginally, and although we found a significant difference in tumour proliferation between low-dose and high-dose nab -paclitaxel (p<0.02), comparison against untreated KPC tumours failed to reach significance ( figure 1 D; p=0.09).

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.